Summary of New Wei Medical Conference Call Company Overview - New Wei Medical focuses on interventional brain-machine interface technology, utilizing a minimally invasive approach through the jugular vein to access brain vessels for signal collection, differentiating itself from invasive technologies like those developed by Musk's company [2][5] Key Points and Arguments - **Product Development Timeline**: New Wei Medical plans to complete type testing and animal experiments by mid-2026, initiate clinical enrollment in the second half of 2026, and expects to finish all patient enrollment and submit for regulatory approval by 2028 [2][3][4] - **Independent Subsidiary**: The company has established an independent subsidiary named "Wei Brain Technology" to focus on the development of interventional brain-machine interfaces and related investment collaborations, with plans to expand the team to 20 members [2][9] - **Technical Specifications**: The interventional brain-machine interface device uses a nickel-titanium alloy stent with electrode configurations of 4 or 16 channels, with signal processing chips placed subcutaneously beneath the clavicle [2][8] - **Animal Testing Results**: Animal experiments have shown stable signal strength, with a small-tailed sheep experiment maintaining 97%-98% signal strength after 18 months, validating the feasibility of the technology [2][11] Competitive Landscape - **Comparison with Musk's Technology**: New Wei Medical's approach avoids the need for craniotomy, which is required by Musk's invasive technology. This results in lower surgical risks and higher patient acceptance. The company claims its method ensures stable signal transmission due to the encapsulation of the electrode stent by the vessel wall, preventing displacement issues [5][10] Clinical Trial Plans - **First Patient Enrollment**: The company plans to conduct its first clinical trial in 2026, targeting 30-50 patients primarily for limb rehabilitation indications, with a follow-up period of approximately six months [4][10] - **Regulatory Recognition**: New Wei Medical is the only approved project for interventional technology routes in a national initiative co-hosted by the Ministry of Industry and Information Technology and the National Medical Products Administration, indicating recognition of its innovative technology [4][6] Challenges and Future Directions - **Technical Limitations**: The interventional approach may face challenges in accessing smaller, more distal blood vessels, necessitating the design of smaller electrode stents for broader brain area applications [11][12] - **Future Applications**: The company aims to extend its technology from motor function areas to visual and auditory functions, as well as explore emotional management and other research directions [11][12] Additional Insights - **Market Potential**: With 2,500 hospitals in China capable of performing the minimally invasive procedure, New Wei Medical is positioned to leverage a broad market for its technology [5] - **Investment and Collaboration**: The subsidiary aims to attract external partnerships and capital to enhance its operational capabilities and cover more consumer-level application scenarios [9]

证券日报网讯1月8日，亿道信息（001314）在互动平台回答投资者提问时表示，公司曾在2023年与相关 领域公司就非侵入式脑机接口的头盔产品做过原型机探索，但目前公司尚未有实际量产的产品涉足该领 域。公司会持续关注脑机接口技术的发展与成熟时机。 ...

Core Insights - Strong Brain Technology, a brain-computer interface "unicorn," recently completed approximately 2 billion yuan in financing, making it the second-largest financing in the global brain-computer interface sector, following Neuralink [1] - The financing round attracted prestigious investors, including IDG Capital, Huaden International founded by Intel CEO Chen Lifeng, and several technology and education companies [1] - The brain-computer interface sector has seen a surge in secondary capital, with the sector's stocks rising over 20% in the last three trading days [1] Company Overview - Founded in 2015, Strong Brain Technology is recognized alongside innovative companies like DeepSeek and Yuzhu Technology as part of the "Hangzhou Six Little Dragons" [1] - Unlike Neuralink, Strong Brain Technology focuses on the development of non-invasive brain-computer interface technology [1] - The company's products span rehabilitation medicine, smart health, and intelligent education, with FDA and CE certifications obtained [1] Product and Market Potential - The core product, "Super Sensor," can detect weak brain electrical signals without invasive procedures, converting them into neural signals to control external devices [1] - The product currently assists individuals with physical disabilities in performing activities like running and complex sports [2] - Strong Brain Technology aims to help 1 million disabled individuals regain mobility and assist 10 million patients with Alzheimer's, autism, and insomnia over the next 5-10 years [2] Financial and Investment Highlights - Strong Brain Technology has attracted significant investment since its inception, completing multiple funding rounds, including a $400 million Series A in 2019 and subsequent rounds totaling $30 million and $20 million [2] - As of 2024, the company's valuation stands at 8.5 billion yuan according to the Hurun Global Unicorn List [2] - The company is reportedly preparing for an IPO, potentially in Hong Kong or mainland China, after completing over $100 million in pre-IPO financing by 2025 [2] Industry Trends - According to research from Open Source Securities, brain-computer interface technology is expected to commercialize by 2026, expanding from medical necessities into AI applications and robotics [2] - The commercialization path for non-invasive products is clear, indicating significant revenue potential in the future [2]

Summary of the Conference Call for Meihow Medical Company Overview - Meihow Medical focuses on medical device CDMO, covering areas such as respiratory care, cochlear implants, blood glucose management, and cardiovascular surgical interventions, with full-process production capabilities and relevant qualifications [2][3] Key Business Segments - The company has made significant progress in cochlear implants, utilizing a sound processor to convert external sounds into multiple frequency bands, transmitted to the inner ear via platinum wires, with a unit price of approximately $1,000 and a gross margin of 60%-70% [2][6] - Meihow Medical is developing implantable brain-machine interface (BMI) devices, leveraging its cochlear implant experience, with expected gross margins similar to cochlear implants once mass production begins [2][7] Brain-Machine Interface Technology - BMI technology is categorized into output, input, and interactive types, with applications in medical rehabilitation, mental health, education, and entertainment [4][5] - The company anticipates BMI new business revenue to reach millions to tens of millions of RMB by 2025, with potential for significant growth in 2026 [4][16] Market Outlook - In 2026, Meihow Medical expects a recovery in its main business, with double-digit growth in home respiratory devices and cochlear implants, and above-average growth in blood glucose and consumer segments [4][22] - The company’s BMI products are still in the early industrial stage, with current revenue from cochlear implants around 100 million RMB, 50% of which comes from invasive electrode pieces [15] Collaboration and Client Relationships - 90% of Meihow Medical's business comes from overseas exports, with collaborations with leading companies in the BMI field [17][18] - The company has established a strong reputation due to its long-term experience in processing Class III materials, which is a key consideration for clients when selecting suppliers [19] Challenges and Innovations - Long-term implant technology is a complex system engineering challenge, requiring integration of process technology to ensure stability under long-term conditions [21] - The company is also exploring semi-invasive and non-invasive products, aiming to enhance the effectiveness of non-invasive devices through invasive technology [12][13] Future Developments - Meihow Medical is expanding into humanoid robotics, leveraging existing technologies and planning to fill production capacity in emerging consumer electronics markets [25] - The company’s Malaysian factory is expected to stabilize profit margins and net profits as production scales up [24] Conclusion - Overall, Meihow Medical is positioned for growth in the medical device sector, particularly in cochlear implants and brain-machine interfaces, with a strong focus on innovation and collaboration with industry leaders [2][4][16]

Summary of Key Points from the Conference Call Industry Overview - The conference call focused on the **brain-computer interface (BCI)** technology, which is categorized into invasive, semi-invasive, and non-invasive types, each with its own advantages and disadvantages [1][3][4]. Core Insights and Arguments - **Non-invasive BCIs** are primarily used for typing communication (based on P300), device control (based on SSVEP), and rehabilitation training (based on motor imagery potentials). However, they face limitations due to skull interference, resulting in low amplitude brain waves and a need for improved decoding accuracy [1][11][13]. - **Invasive BCIs** have made progress in motor and language decoding, as well as visual and auditory reconstruction, but they carry risks such as bleeding, infection, and device reliability issues, leading to uncertainty in commercialization prospects [1][15]. - A research team is exploring a hybrid approach combining **EEG and EMG** to decode motor intentions by analyzing weak muscle signals, which has shown success in helping patients with arm injuries and strokes regain some limb function, with plans for commercial use by mid-2025 [1][16][17]. - The market potential for hand function rehabilitation in China is significant, with over **50 million** patients suffering from limb disabilities and an annual increase of **2 to 3 million** cases [1][18]. Additional Important Content - The **clinical application** of EEG differs from BCI research, requiring higher sampling rates (1,000 Hz to 20,000 Hz) for effective data quality in BCI applications compared to the lower rates used in clinical settings [2]. - The **hardware segment** of the BCI industry has high barriers to entry and substantial profit margins, making it a promising investment area, especially in the context of China's healthcare payment habits [24]. - **Neuralink**, a prominent player in the invasive BCI space, has raised questions about its valuation and the practical benefits of its technology compared to non-invasive alternatives [23][22]. - The **supply chain** for BCI products is influenced by the compatibility of cost control and healthcare payment systems, particularly for non-invasive rehabilitation and invasive surgeries [24]. - Future applications of BCI technology may extend to treating mental health disorders and cognitive enhancement, although these areas still face significant challenges in decoding complex brain functions [26]. This summary encapsulates the key points discussed in the conference call, highlighting the current state and future potential of brain-computer interface technology.

Summary of Neural Interface Technology Conference Industry Overview - The conference focused on the neural interface technology industry, particularly advancements made by Neuralink and domestic companies in China [1][3][4][5][10]. Key Points and Arguments Neuralink's Advancements - Neuralink has significantly reduced the cost of implantable devices, with fixture costs dropping by 95%, from approximately $5,000-$6,000 to a few hundred dollars [1][3][4]. - The electrode production cost remains high, at over $10,000 per electrode, but the implantation speed has improved from 20 seconds to 1.5 seconds per electrode, facilitating clinical applications [1][3][4]. - The company has entered clinical trials, utilizing BlackRock electrodes and developing its own implantation devices that combine electron microscopy and OCR systems for precise electrode placement [1][8][9]. Challenges in Neural Interface Technology - The industry faces challenges such as complex electrode production processes, low yield rates, and patent barriers, particularly regarding non-invasive puncture techniques patented by Musk [1][5][6]. - Domestic companies need breakthroughs in materials, processes, and patent strategies to compete effectively [1][5]. Comparison of Invasive and Semi-Invasive Techniques - Neuralink's fully invasive technology targets complex diseases, while domestic companies like BoruiKang focus on semi-invasive methods primarily for rehabilitation, which are less risky and costly [1][7][10]. - The main difference lies in the application: fully invasive techniques aim to treat severe conditions through deep neural stimulation, whereas semi-invasive methods are used for rehabilitation by repairing damaged nerves [1][7]. Domestic Industry Landscape - Domestic companies such as JieTi, Tiger Technology, and WeiLing have made progress in flexible electrodes but still lag behind international leaders like Neuralink in terms of channel count (128 channels vs. Neuralink's 1,024 channels) and other technical specifications [1][10]. - The downstream applications of the domestic neural interface industry account for 70% of the market share, focusing on rehabilitation devices and commercial products, while upstream investments in electrode and chip development are capital-intensive [1][10]. Clinical Applications and Future Directions - BoruiKang's semi-quantitative methods have been widely adopted in over 20 hospitals in China, with more than 200 clinical trials conducted in 2024 [12]. - The potential for interventionist neural interfaces is highlighted, with successful trials indicating a promising future if challenges like vascular blockage can be addressed [2][16]. Competitive Landscape - Companies like Medtronic have received FDA approval for their brain stimulators, showing significant efficacy in treating conditions like epilepsy, while competitors like Pinchi Medical face challenges due to patent restrictions [14][25]. - The market for deep brain stimulation (DBS) devices is still developing, with no fully mature embedded products available yet [25]. Additional Important Insights - The domestic neural interface industry is characterized by a high investment threshold in the upstream sector, with a typical investment ratio of 3:1 or 4:1 favoring downstream applications [10]. - The technology's application in treating neurological diseases is expanding, with potential uses in conditions like Alzheimer's and depression through adaptive neural regulation [19]. This summary encapsulates the key discussions and insights from the neural interface technology conference, highlighting both advancements and challenges within the industry.

Core Viewpoint - The establishment of Gestalt Technology Co., Ltd. marks a significant advancement in non-invasive ultrasound brain-computer interface (BCI) technology, offering a new pathway in the BCI field [1][2]. Group 1: Technology Overview - Gestalt Technology specializes in ultrasound and phased array technology, differentiating itself from traditional invasive BCI methods [1]. - The non-invasive ultrasound BCI can modulate brain functions without the need for surgical procedures, unlike traditional invasive techniques that require drilling into the skull [1]. - The technology allows for high spatiotemporal resolution monitoring of brain signals, making it a promising direction for full-brain read/write capabilities [1]. Group 2: Product Development and Clinical Applications - The company plans to develop multiple generations of products, starting with a bench-top device, followed by a wearable device, and ultimately a semi-implantable device [2]. - The first product focuses on chronic pain management, currently undergoing clinical trials, with plans to initiate the registration process with the National Medical Products Administration by the end of the year [2]. - Clinical data shows significant potential, with pain intensity in chronic pain management reduced significantly and sustained for a week, and improvements in mood and depression scores within 24 hours for depression interventions [2]. Group 3: Collaborative Efforts and Industry Support - Gestalt Technology has established partnerships with several prestigious hospitals, including Fudan University Huashan Hospital and Peking Union Medical College Hospital, to enhance "industry-university-research-medical" collaboration [2]. - The collaboration aims to accelerate the clinical translation of ultrasound BCI technology, facilitating faster patient service [2]. - Sichuan Province has launched a special policy to promote the BCI industry, aiming to create a leading innovation development hub for BCI and human-computer interaction by 2030 [2][3]. Group 4: Ecosystem Development - The establishment of Gestalt Technology contributes to the formation of a more complete BCI ecosystem in Chengdu, leveraging the region's comprehensive resources in research, clinical practice, and medical innovation [3]. - The presence of top-tier clinical and research capabilities, exemplified by Sichuan University Huaxi Hospital, provides essential support for the innovation of medical devices like BCI [3].

Core Viewpoint - The Shanghai Stock Exchange has issued an inquiry letter to Yahui Long, requesting additional disclosure regarding its strategic cooperation with Shenzhen Brain Machine Star Chain Technology Co., Ltd. [2] Group 1: Cooperation Details - Yahui Long signed a strategic cooperation framework agreement with Brain Machine Star Chain on January 6, focusing on clinical transformation and market expansion of brain-machine interface technology [2][4] - The cooperation will involve market promotion and revenue sharing [4] Group 2: Inquiry Requirements - The Shanghai Stock Exchange requires Yahui Long to disclose the main technical routes, product types, application fields, and commercialization status of Brain Machine Star Chain [5] - Yahui Long must analyze the feasibility of market promotion collaboration based on its main business and the synergies with Brain Machine Star Chain [5] - The company is also required to provide a timeline for future promotional agreements and expected revenue sharing [5] Group 3: Product Development Status - Brain Machine Star Chain, established in September 2025, is developing products such as EEG analysis devices and non-invasive brain-machine interface devices, which are still in early development stages [4][6] - The vagus nerve stimulation device is in the registration preparation stage, while other products are in early research or preclinical stages [4] Group 4: Financial Performance and Investment Feasibility - Yahui Long's revenue and net profit for the first three quarters of 2025 decreased by 7.69% and 72.36% year-on-year, respectively, with cash reserves of 465 million yuan [10][13] - The company plans to provide financial and business support to Brain Machine Star Chain through equity investment or joint ventures [10][13] - Yahui Long stated that the strategic cooperation will not significantly impact its performance in the short term [13]

当前，脑机接口技术正推开规模化应用的大门。 跨年前夜，当"钢铁侠"马斯克在社交媒体上宣布2026年"神经连接"（Neuralink）将"大规模生产"脑机接 口设备，并转向"更加精简和几乎完全自动化的外科手术流程"时，世界的目光再次聚焦这场将重塑人机 关系的科技狂想。 事实上，在这场全球科技竞赛中，中国不再是追随者——从十年前默默耕耘，到如今在非侵入式赛道引 领风潮，以杭州"六小龙"之一的强脑科技（BrainCo）为代表的中国力量，已站上国际舞台中央。其创 始人兼CEO韩璧丞，这位哈佛博士未毕业就创业的"疯狂科学家"，正带领强脑科技向世界展示一条迥异 于Neuralink的东方路径：不追求以手术刀撬开颅骨的"连接"，而致力于用算法与传感解开大脑信号 的"密码"。 这背后，究竟藏着怎样的故事？ 高中毕业后，这位东北少年踏上了一条不寻常的国际化科研之路。 在韩国科学技术院（KAIST），一次偶然的学术探寻让韩璧丞了解到美国匹兹堡大学一项开创性实验： 一只猴子可以通过脑机接口控制机械臂给自己喂食可口的香蕉。"如果人类能直接用意念操控机器将带 来怎样的革命？" 为了离这个问题的答案更近一步，韩璧丞于2011年加入位于美 ...

2026年1月5日午后，创业板新能源ETF华夏（159368）涨幅扩大至2.52%。盘面上，成分股普涨，仅4只 个股下跌，道氏技术涨停，罗博特科上涨12.20%，先导智能、富临精工等涨超6%；截至发文，创业板 新能源ETF华夏（159368）成交额达6227万元，居同类基金首位。 消息面上，埃隆·马斯克2025年12月31日通过社交平台发布重磅消息，旗下脑机接口公司Neuralink计划 于2026年启动脑机接口设备大规模量产，并同步推出全自动化外科手术流程。这一规划标志着脑机接口 技术从临床验证阶段向产业化落地迈出关键一步，也成为A股人脑工程板块的强力催化。 公司面上，12月25日，道氏技术控股子公司认购强脑科技Pre-B轮优先股完成交割，推进碳材料在脑机 接口、电子皮肤等前沿领域的应用。作为国内最早量产单壁碳纳米管的企业之一，公司单壁碳纳米管粉 体性能已与进口产品相当，也是脑机接口电极材料的关键导电增强剂。 创业板新能源ETF华夏（159368）是全市场跟踪创业板新能源指数的规模最大ETF基金。创业板新能源 指数主要涵盖新能源和新能源汽车产业，涉及电池、光伏等多个细分领域。创业板新能源ETF华夏 （159 ...